Market Overview:
The global atherosclerosis therapeutics market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of atherosclerosis, rising geriatric population, and technological advancements in the field of atherosclerosis therapeutics. The global atherosclerosis therapeutics market is segmented on the basis of type into small molecules and biologics. The small molecules segment is expected to dominate the global Atherosclerosis Therapeutics Market by 2030 owing to their high efficacy and low cost as compared to biologics. On the basis of application, hospital accounted for majority share in 2017 and it is projected that this trend would continue during forecast period due high prevalence rateof cardiovascular diseases (CVDs) across globe . Clinic held second largest share in 2017and itis projected that this trend would continue during forecast period due growing awareness about early diagnosis & treatment options for CVDs among people across globe .
Product Definition:
Atherosclerosis is a disease state in which the walls of an artery become thickened and hardened as a result of the accumulation of fatty material (plaque) on their inner lining. The plaque reduces the diameter of the artery, leading to restricted blood flow and, potentially, to heart attack or stroke. Atherosclerosis Therapeutics are drugs that are used to treat this condition by reducing or preventing the build-up of plaque in arteries.
Small Molecules:
Small molecules are the most basic and common type of drug used by doctors to treat any disease or illness. Small molecule drugs can be extracted from nature (like vitamins) or can be manufactured in a laboratory. They are usually easy to produce, cost-effective, and have few side effects associated with them.
The global small molecules, it's usage & growth factor in atherosclerosis therapeutics market size was valued at USD 469 billion in 2015.
Biologics:
Biologics are living organisms which are used for the treatment of diseases. They have advantages over conventional drugs as they can interact with the disease-causing agents (tumor cells or bacteria) and block their normal functioning. Biologics also have greater safety and efficacy, improved dosing schedule & better tolerance by patients due to which it is being preferred by healthcare professionals globally.
Application Insights:
The other application segment accounted for the largest revenue share in 2017 and is expected to continue its dominance over the forecast period. The atherosclerosis treatment market has witnessed a rise in demand with respect to small molecules as well as biologics. With an increase in patient population, there is a need for advanced therapeutics that can treat multiple co-morbidities of cardiovascular diseases such as diabetes and hyperlipidemia.
Clinical trials have proven that lifestyle modification along with drug therapy reduces the risk factors associated with atherosclerosis thus improving clinical outcomes. However, these risk factors are difficult to modify owing to various reasons including lack of knowledge about modifiable lifestyle habits among patients suffering from chronic diseases, healthcare professionals being unfamiliarized with these methods or their unavailability due to cost constraints among others.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period owing to high R&D investments and rising prevalence of atherosclerosis. In addition, increasing adoption of a sedentary lifestyle and growing consumer awareness about risk factors associated with cardiovascular diseases are contributing toward regional growth.
Asia Pacific is estimated to be the fastest-growing region over the forecast period due to unmet clinical needs, availability of effective treatment methods, increase in disposable income levels, rise in consumer awareness about atherosclerosis risks & benefits as well as government initiatives for improving healthcare facilities at an affordable cost within this region. Moreover, favorable regulatory policies are also anticipated to drive regional growth over the coming years. For instance, China’s State Council has approved new regulations that allow foreign companies like Johnson & Johnson Services India Ltd.
Growth Factors:
- Increasing prevalence of atherosclerosis and its associated complications: The global prevalence of atherosclerosis is estimated to be around 15-20%. This number is expected to grow significantly in the coming years due to increasing incidence of obesity, diabetes, and other risk factors. This will create a large pool of patients who will require treatment for atherosclerosis and its complications.
- Growing awareness about the risks and symptoms associated with atherosclerosis: There is growing awareness among people about the risks and symptoms associated with atherosclerosis. This is helping to increase demand for therapies for the condition.
- Advances in technology and drug development: The field of Atherosclerosis Therapeutics is constantly evolving with new advances in technology and drug development. This is helping to improve patient outcomes and increase adoption rates for these therapies.
Scope Of The Report
Report Attributes
Report Details
Report Title
Atherosclerosis Therapeutics Market Research Report
By Type
Small Molecules, Biologics
By Application
Hospital, Clinic, Research Institute, Other
By Companies
AstraZeneca Plc, Bayer AG, Merck & Co. Inc., Novartis AG, Sanofi
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
125
Number of Tables & Figures
88
Customization Available
Yes, the report can be customized as per your need.
Global Atherosclerosis Therapeutics Market Report Segments:
The global Atherosclerosis Therapeutics market is segmented on the basis of:
Types
Small Molecules, Biologics
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Research Institute, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca Plc
- Bayer AG
- Merck & Co. Inc.
- Novartis AG
- Sanofi
Highlights of The Atherosclerosis Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Small Molecules
- Biologics
- By Application:
- Hospital
- Clinic
- Research Institute
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Atherosclerosis Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Atherosclerosis Therapeutics is a biotechnology company focused on the development of novel therapeutics to treat atherosclerosis. The company's products include small molecule drugs and antibody-drug conjugates (ADCs).
Some of the key players operating in the atherosclerosis therapeutics market are AstraZeneca Plc, Bayer AG, Merck & Co. Inc., Novartis AG, Sanofi.
The atherosclerosis therapeutics market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Atherosclerosis Therapeutics Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Atherosclerosis Therapeutics Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Atherosclerosis Therapeutics Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Atherosclerosis Therapeutics Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Atherosclerosis Therapeutics Market Size & Forecast, 2018-2028 4.5.1 Atherosclerosis Therapeutics Market Size and Y-o-Y Growth 4.5.2 Atherosclerosis Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Atherosclerosis Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Atherosclerosis Therapeutics Market Size Forecast by Type
5.2.1 Small Molecules
5.2.2 Biologics
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Atherosclerosis Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Atherosclerosis Therapeutics Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Research Institute
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Atherosclerosis Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Atherosclerosis Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Atherosclerosis Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Atherosclerosis Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Atherosclerosis Therapeutics Market Size Forecast by Type
9.6.1 Small Molecules
9.6.2 Biologics
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Atherosclerosis Therapeutics Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Research Institute
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Atherosclerosis Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Atherosclerosis Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Atherosclerosis Therapeutics Market Size Forecast by Type
10.6.1 Small Molecules
10.6.2 Biologics
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Atherosclerosis Therapeutics Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Research Institute
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Atherosclerosis Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Atherosclerosis Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Atherosclerosis Therapeutics Market Size Forecast by Type
11.6.1 Small Molecules
11.6.2 Biologics
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Atherosclerosis Therapeutics Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Research Institute
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Atherosclerosis Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Atherosclerosis Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Atherosclerosis Therapeutics Market Size Forecast by Type
12.6.1 Small Molecules
12.6.2 Biologics
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Atherosclerosis Therapeutics Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Research Institute
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Atherosclerosis Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Atherosclerosis Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Atherosclerosis Therapeutics Market Size Forecast by Type
13.6.1 Small Molecules
13.6.2 Biologics
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Atherosclerosis Therapeutics Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Research Institute
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Atherosclerosis Therapeutics Market: Competitive Dashboard
14.2 Global Atherosclerosis Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca Plc
14.3.2 Bayer AG
14.3.3 Merck & Co. Inc.
14.3.4 Novartis AG
14.3.5 Sanofi